Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Hydrocortisone-valerate | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | | Hydrocortisone-valerate | hsa00030 | Pentose phosphate pathway | 8.97E-03 | 1 | P11413 | G6PD | More | | Hydrocortisone-valerate | hsa00190 | Oxidative phosphorylation | 4.36E-03 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Hydrocortisone-valerate | hsa00220 | Arginine biosynthesis | 1.94E-03 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | Hydrocortisone-valerate | hsa00250 | Alanine, aspartate and glutamate metabolism | 4.32E-02 | 2 | P49448, P15104 | GLUD2, GLUL | More | | Hydrocortisone-valerate | hsa00480 | Glutathione metabolism | 2.60E-05 | 5 | Q9UJ14, P11413, Q16772, P09211, P30041 | GGTL3, G6PD, GSTA3, GSTP1, PRDX6 | More | | Hydrocortisone-valerate | hsa00500 | Starch and sucrose metabolism | 1.18E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Hydrocortisone-valerate | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Hydrocortisone-valerate | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Hydrocortisone-valerate | hsa00730 | Thiamine metabolism | 4.32E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Hydrocortisone-valerate | hsa00910 | Nitrogen metabolism | 4.32E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | | Hydrocortisone-valerate | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.21E-02 | 1 | P14868 | DARS | More | | Hydrocortisone-valerate | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-05 | 4 | Q16772, P78417, P09211, P11712 | GSTA3, GSTO1, GSTP1, CYP2C9 | More | | Hydrocortisone-valerate | hsa00982 | Drug metabolism - cytochrome P450 | 1.77E-04 | 4 | P11712, Q16772, P09211, P78417 | CYP2C9, GSTA3, GSTP1, GSTO1 | More | | Hydrocortisone-valerate | hsa00983 | Drug metabolism - other enzymes | 1.72E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Hydrocortisone-valerate | hsa01100 | Metabolic pathways | 8.43E-03 | 11 | P35790, Q16772, P09211, Q9UJ14, P30041, P40926, Q7KZN9, P15121, Q9UHK6, Q86VZ5, Q9BQB6 | CHKA, GSTA3, GSTP1, GGTL3, PRDX6, MDH2, COX15, AKR1B1, AMACR, SGMS1, VKORC1 | More | | Hydrocortisone-valerate | hsa01200 | Carbon metabolism | 2.91E-02 | 1 | P11413 | G6PD | More | | Hydrocortisone-valerate | hsa01230 | Biosynthesis of amino acids | 3.91E-02 | 3 | P51854, Q99707, P50213 | TKTL1, MTR, IDH3A | More | | Hydrocortisone-valerate | hsa01524 | Platinum drug resistance | 4.44E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Hydrocortisone-valerate | hsa03013 | RNA transport | 9.39E-05 | 9 | Q15287, Q9UBU9, P35658, P63279, P68104, P55884, O15371, P20042, Q14232 | RNPS1, NXF1, NUP214, UBE2I, EEF1A1, EIF3B, EIF3D, EIF2S2, EIF2B1 | More | | Hydrocortisone-valerate | hsa03040 | Spliceosome | 3.98E-02 | 4 | Q15427, P38159, P61978, P11142 | SF3B4, RBMX, HNRPK, HSPA8 | More | | Hydrocortisone-valerate | hsa03060 | Protein export | 9.07E-04 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Hydrocortisone-valerate | hsa04012 | ErbB signaling pathway | 3.74E-02 | 3 | P21860, Q13557, O14944 | ERBB3, CAMK2D, EREG | More | | Hydrocortisone-valerate | hsa04020 | Calcium signaling pathway | 2.19E-05 | 10 | Q96DU7, Q08828, P45880, Q13557, P21860, P61073, P0DP24, P05141, P51828, P23634 | ITPKC, ADCY1, VDAC2, CAMK2D, ERBB3, CXCR4, CALM2, SLC25A5, ADCY7, ATP2B4 | More | | Hydrocortisone-valerate | hsa04022 | cGMP-PKG signaling pathway | 2.45E-03 | 8 | Q99941, P18848, P23634, Q08828, P51828, P05141, P45880, P0DP24 | CREBL1, ATF4, ATP2B4, ADCY1, ADCY7, SLC25A5, VDAC2, CALM2 | More | | Hydrocortisone-valerate | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 9.15E-04 | 9 | Q8NHW4, P09341, P25024, P25025, P61073, P47992, Q9UBD3, Q13651, P01375 | CCL4L2, CXCL1, CXCR1, CXCR2, CXCR4, XCL1, XCL2, IL10RA, TNF | More | | Hydrocortisone-valerate | hsa04062 | Chemokine signaling pathway | 3.13E-02 | 8 | P25024, P25025, P07948, P42338, P63218, P50151, P49407, P49841 | CXCR1, CXCR2, LYN, PIK3CB, GNG5, GNG10, ARRB1, GSK3B | More | | Hydrocortisone-valerate | hsa04064 | NF-kappa B signaling pathway | 9.08E-04 | 8 | Q13489, Q13546, P01584, Q9UDY8, P63279, Q8NHW4, Q9UNE0, Q9NQC7 | BIRC3, RIPK1, IL1B, MALT1, UBE2I, CCL4L2, EDAR, CYLD | More | | Hydrocortisone-valerate | hsa04114 | Oocyte meiosis | 4.36E-02 | 5 | Q13557, P0DP24, Q08828, P51828, P27348 | CAMK2D, CALM2, ADCY1, ADCY7, YWHAQ | More | | Hydrocortisone-valerate | hsa04140 | Autophagy - animal | 3.61E-02 | 5 | Q9NQL2, P22694, Q14643, Q9H1Y0, Q04759 | RRAGD, PRKACB, ITPR1, ATG5, PRKCQ | More | | Hydrocortisone-valerate | hsa04141 | Protein processing in endoplasmic reticulum | 5.75E-03 | 7 | Q99941, O75460, P17861, P11142, Q9H3Z4, P07900, Q9NR31 | CREBL1, ERN1, XBP1, HSPA8, DNAJC5, HSP90AA1, SAR1A | More | | Hydrocortisone-valerate | hsa04150 | mTOR signaling pathway | 2.72E-02 | 4 | P42338, Q9NQL2, Q13322, P49841 | PIK3CB, RRAGD, GRB10, GSK3B | More | | Hydrocortisone-valerate | hsa04211 | Longevity regulating pathway | 3.41E-03 | 7 | Q12778, Q08828, P51828, Q99941, P18848, Q9UEF7, Q96KQ7 | FOXO1, ADCY1, ADCY7, CREBL1, ATF4, KL, EHMT2 | More | | Hydrocortisone-valerate | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | | Hydrocortisone-valerate | hsa04217 | Necroptosis | 6.23E-04 | 10 | P01568, P23458, Q13489, Q9NQC7, Q13546, P05141, P01584, P0C0S5, Q13557, Q9H444 | IFNA21, JAK1, BIRC3, CYLD, RIPK1, SLC25A5, IL1B, H2AFZ, CAMK2D, CHMP4B | More | | Hydrocortisone-valerate | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.60E-03 | 7 | Q08828, P51828, Q99941, P18848, P0DP24, Q13557, P23634 | ADCY1, ADCY7, CREBL1, ATF4, CALM2, CAMK2D, ATP2B4 | More | | Hydrocortisone-valerate | hsa04330 | Notch signaling pathway | 4.34E-02 | 2 | Q92542, P46531 | NCSTN, NOTCH1 | More | | Hydrocortisone-valerate | hsa04380 | Osteoclast differentiation | 6.08E-03 | 10 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P42338, P01584, P14778, O75015, Q8N149 | CYLD, GAB2, MAPK14, JAK1, LCK, PIK3CB, IL1B, IL1R1, FCGR3B, LILRA2 | More | | Hydrocortisone-valerate | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Hydrocortisone-valerate | hsa04612 | Antigen processing and presentation | 3.60E-03 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Hydrocortisone-valerate | hsa04613 | Neutrophil extracellular trap formation | 4.90E-05 | 18 | P11215, O60603, P05164, P08246, Q9UM07, Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431, P20160, P08311, O75015, P21730, O43315, Q16539 | ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AZU1, CTSG, FCGR3B, C5AR1, AQP9, MAPK14 | More | | Hydrocortisone-valerate | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | | Hydrocortisone-valerate | hsa04621 | NOD-like receptor signaling pathway | 3.13E-04 | 17 | Q16539, Q14643, P01568, Q13489, P10599, Q9H1Y0, P43490, O00463, Q13546, P29728, Q05823, P01375, P09341, P49913, P59665, P59666, P12838 | MAPK14, ITPR1, IFNA21, BIRC3, TXN, ATG5, PBEF1, TRAF5, RIPK1, OAS2, RNASEL, TNF, CXCL1, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Hydrocortisone-valerate | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Hydrocortisone-valerate | hsa04623 | Cytosolic DNA-sensing pathway | 5.86E-05 | 4 | P01584, P01568, Q13546, Q8NHW4 | IL1B, IFNA21, RIPK1, CCL4L2 | More | | Hydrocortisone-valerate | hsa04640 | Hematopoietic cell lineage | 1.10E-02 | 9 | P13612, P14778, P27930, P15144, P25063, P09693, P01732, P13765, P01375 | ITGA4, IL1R1, IL1R2, ANPEP, CD24, CD3G, CD8A, HLA-DOB, TNF | More | | Hydrocortisone-valerate | hsa04650 | Natural killer cell mediated cytotoxicity | 3.11E-04 | 9 | P01375, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Hydrocortisone-valerate | hsa04657 | IL-17 signaling pathway | 1.42E-02 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Hydrocortisone-valerate | hsa04658 | Th1 and Th2 cell differentiation | 5.29E-06 | 12 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, Q14765, P23771, Q9UL17, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, STAT4, GATA3, TBX21, HLA-DOB, RUNX3 | More | | Hydrocortisone-valerate | hsa04659 | Th17 cell differentiation | 1.31E-04 | 11 | Q04759, Q16539, P01730, P06239, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, MAPK14, CD4, LCK, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Hydrocortisone-valerate | hsa04660 | T cell receptor signaling pathway | 6.26E-05 | 14 | P01375, Q04759, P42338, O95267, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Hydrocortisone-valerate | hsa04662 | B cell receptor signaling pathway | 2.80E-03 | 6 | P49841, P42338, P60033, P07948, P21854, Q8N149 | GSK3B, PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Hydrocortisone-valerate | hsa04664 | Fc epsilon RI signaling pathway | 1.80E-02 | 4 | Q16539, P42338, P07948, P09917 | MAPK14, PIK3CB, LYN, ALOX5 | More | | Hydrocortisone-valerate | hsa04668 | TNF signaling pathway | 4.74E-02 | 3 | Q99941, P01584, O95429 | CREBL1, IL1B, BAG4 | More | | Hydrocortisone-valerate | hsa04713 | Circadian entrainment | 1.91E-02 | 4 | P0DP24, Q13557, Q08828, P51828 | CALM2, CAMK2D, ADCY1, ADCY7 | More | | Hydrocortisone-valerate | hsa04720 | Long-term potentiation | 1.91E-02 | 4 | Q13557, P0DP24, P18848, Q08828 | CAMK2D, CALM2, ATF4, ADCY1 | More | | Hydrocortisone-valerate | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Hydrocortisone-valerate | hsa04723 | Retrograde endocannabinoid signaling | 3.86E-02 | 4 | P63218, P50151, P48058, Q16539 | GNG5, GNG10, GRIA4, MAPK14 | More | | Hydrocortisone-valerate | hsa04724 | Glutamatergic synapse | 7.09E-03 | 5 | P48058, P43003, P63218, P50151, P15104 | GRIA4, SLC1A3, GNG5, GNG10, GLUL | More | | Hydrocortisone-valerate | hsa04725 | Cholinergic synapse | 3.77E-02 | 4 | Q08828, P51828, P18848, Q13557 | ADCY1, ADCY7, ATF4, CAMK2D | More | | Hydrocortisone-valerate | hsa04728 | Dopaminergic synapse | 1.73E-03 | 11 | P63218, P50151, P49841, Q99941, P18848, Q16539, Q13557, P49407, P0DP24, O15516, P48058 | GNG5, GNG10, GSK3B, CREBL1, ATF4, MAPK14, CAMK2D, ARRB1, CALM2, CLOCK, GRIA4 | More | | Hydrocortisone-valerate | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.58E-05 | 10 | P14778, P01584, Q08828, P51828, P22694, Q13557, Q16539, Q14643, Q04759, P0DP24 | IL1R1, IL1B, ADCY1, ADCY7, PRKACB, CAMK2D, MAPK14, ITPR1, PRKCQ, CALM2 | More | | Hydrocortisone-valerate | hsa04911 | Insulin secretion | 2.95E-05 | 5 | Q08828, P51828, Q99941, P18848, Q13557 | ADCY1, ADCY7, CREBL1, ATF4, CAMK2D | More | | Hydrocortisone-valerate | hsa04912 | GnRH signaling pathway | 6.99E-03 | 5 | Q08828, P51828, P18848, Q13557, P0DP24 | ADCY1, ADCY7, ATF4, CAMK2D, CALM2 | More | | Hydrocortisone-valerate | hsa04915 | Estrogen signaling pathway | 4.72E-02 | 4 | Q99941, P51828, P07900, P11142 | CREBL1, ADCY7, HSP90AA1, HSPA8 | More | | Hydrocortisone-valerate | hsa04916 | Melanogenesis | 7.61E-03 | 4 | Q13557, P0DP24, Q08828, P51828 | CAMK2D, CALM2, ADCY1, ADCY7 | More | | Hydrocortisone-valerate | hsa04918 | Thyroid hormone synthesis | 4.47E-03 | 5 | Q08828, P51828, Q99941, P18848, P02768 | ADCY1, ADCY7, CREBL1, ATF4, ALB | More | | Hydrocortisone-valerate | hsa04925 | Aldosterone synthesis and secretion | 8.00E-06 | 7 | Q99941, P18848, Q08828, P51828, P0DP24, Q13557, P23634 | CREBL1, ATF4, ADCY1, ADCY7, CALM2, CAMK2D, ATP2B4 | More | | Hydrocortisone-valerate | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 4 | Q99941, P18848, Q08828, P51828 | CREBL1, ATF4, ADCY1, ADCY7 | More | | Hydrocortisone-valerate | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.77E-02 | 4 | Q08828, P51828, Q99941, P18848 | ADCY1, ADCY7, CREBL1, ATF4 | More | | Hydrocortisone-valerate | hsa04932 | Non-alcoholic fatty liver disease | 3.45E-02 | 5 | P18848, O75460, P01584, P12074, O15239 | ATF4, ERN1, IL1B, COX6A1, NDUFA1 | More | | Hydrocortisone-valerate | hsa04934 | Cushing syndrome | 2.69E-06 | 6 | Q99941, P18848, Q08828, P51828, O15169, Q13557 | CREBL1, ATF4, ADCY1, ADCY7, AXIN1, CAMK2D | More | | Hydrocortisone-valerate | hsa04935 | Growth hormone synthesis, secretion and action | 4.98E-02 | 4 | Q08828, P51828, Q99941, P18848 | ADCY1, ADCY7, CREBL1, ATF4 | More | | Hydrocortisone-valerate | hsa04970 | Salivary secretion | 3.54E-02 | 3 | Q08828, P51828, P0DP24 | ADCY1, ADCY7, CALM2 | More | | Hydrocortisone-valerate | hsa04971 | Gastric acid secretion | 2.95E-05 | 5 | Q08828, P51828, P15311, P0DP24, Q13557 | ADCY1, ADCY7, VIL2, CALM2, CAMK2D | More | | Hydrocortisone-valerate | hsa04973 | Carbohydrate digestion and absorption | 1.57E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Hydrocortisone-valerate | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | | Hydrocortisone-valerate | hsa05010 | Alzheimer disease | 2.56E-05 | 17 | Q92542, O15239, P05496, Q06055, P12074, Q00535, O75460, P0DP24, P01584, P18848, O15169, P05141, P45880, P17861, P28070, P43686, P62195 | NCSTN, NDUFA1, ATP5G1, ATP5G2, COX6A1, CDK5, ERN1, CALM2, IL1B, ATF4, AXIN1, SLC25A5, VDAC2, XBP1, PSMB4, PSMC4, PSMC5 | More | | Hydrocortisone-valerate | hsa05012 | Parkinson disease | 5.28E-04 | 12 | O15239, P12074, Q06055, P05141, O75460, P18848, P17861, P28070, P43686, P62195, P0DP24, Q13557 | NDUFA1, COX6A1, ATP5G2, SLC25A5, ERN1, ATF4, XBP1, PSMB4, PSMC4, PSMC5, CALM2, CAMK2D | More | | Hydrocortisone-valerate | hsa05014 | Amyotrophic lateral sclerosis | 1.01E-02 | 3 | Q06055, P17861, P62195 | ATP5G2, XBP1, PSMC5 | More | | Hydrocortisone-valerate | hsa05016 | Huntington disease | 3.54E-02 | 8 | O15239, P12074, P24928, P62487, P05141, O75460, P28070, P43686 | NDUFA1, COX6A1, POLR2A, POLR2G, SLC25A5, ERN1, PSMB4, PSMC4 | More | | Hydrocortisone-valerate | hsa05017 | Spinocerebellar ataxia | 1.42E-02 | 2 | P17861, P62195 | XBP1, PSMC5 | More | | Hydrocortisone-valerate | hsa05020 | Prion disease | 1.76E-03 | 12 | P01584, P46531, P11142, O15239, P05496, P12074, P18848, P05141, P45880, P28070, P43686, Q99941 | IL1B, NOTCH1, HSPA8, NDUFA1, ATP5G1, COX6A1, ATF4, SLC25A5, VDAC2, PSMB4, PSMC4, CREBL1 | More | | Hydrocortisone-valerate | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.12E-04 | 16 | O15239, P12074, Q06055, Q8TEV9, O75460, P18848, P17861, P05141, Q00535, O15169, P01584, P0DP24, Q13557, P28070, P43686, P62195 | NDUFA1, COX6A1, ATP5G2, SMCR8, ERN1, ATF4, XBP1, SLC25A5, CDK5, AXIN1, IL1B, CALM2, CAMK2D, PSMB4, PSMC4, PSMC5 | More | | Hydrocortisone-valerate | hsa05030 | Cocaine addiction | 3.54E-02 | 3 | Q00535, Q99941, P18848 | CDK5, CREBL1, ATF4 | More | | Hydrocortisone-valerate | hsa05031 | Amphetamine addiction | 7.61E-03 | 4 | P0DP24, Q13557, Q99941, P18848 | CALM2, CAMK2D, CREBL1, ATF4 | More | | Hydrocortisone-valerate | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Hydrocortisone-valerate | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.72E-02 | 4 | Q16539, P25024, P25025, P07948 | MAPK14, CXCR1, CXCR2, LYN | More | | Hydrocortisone-valerate | hsa05132 | Salmonella infection | 9.85E-03 | 4 | Q13546, Q13489, O60282, P68371 | RIPK1, BIRC3, KIF5C, TUBB2C | More | | Hydrocortisone-valerate | hsa05134 | Legionellosis | 5.53E-03 | 2 | Q9NR31, P68104 | SAR1A, EEF1A1 | More | | Hydrocortisone-valerate | hsa05135 | Yersinia infection | 1.11E-03 | 8 | P13612, P06239, Q16539, P01375, P42338, P49841, P01730, P01732 | ITGA4, LCK, MAPK14, TNF, PIK3CB, GSK3B, CD4, CD8A | More | | Hydrocortisone-valerate | hsa05140 | Leishmaniasis | 5.15E-04 | 10 | P13612, O75015, P14598, P13765, O60603, P25963, P01375, P29350, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, HLA-DOB, TLR2, NFKBIA, TNF, PTPN6, MAPK14, NCF4 | More | | Hydrocortisone-valerate | hsa05144 | Malaria | 6.84E-04 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Hydrocortisone-valerate | hsa05146 | Amoebiasis | 5.94E-04 | 9 | P09341, P14778, P27930, P01375, O60603, P05089, P22694, P12814, P08311 | CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, ACTN1, CTSG | More | | Hydrocortisone-valerate | hsa05150 | Staphylococcus aureus infection | 1.02E-03 | 7 | P21730, P21462, O75015, P59665, P59666, P12838, P49913 | C5AR1, FPR1, FCGR3B, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | | Hydrocortisone-valerate | hsa05163 | Human cytomegalovirus infection | 8.52E-07 | 21 | P42338, P01375, P63218, P50151, Q14643, P0DP24, Q8NHW4, Q08828, P51828, P22694, P23458, P49841, P14778, P01584, P61073, Q13651, P25025, Q16539, Q99941, P18848, O00463 | PIK3CB, TNF, GNG5, GNG10, ITPR1, CALM2, CCL4L2, ADCY1, ADCY7, PRKACB, JAK1, GSK3B, IL1R1, IL1B, CXCR4, IL10RA, CXCR2, MAPK14, CREBL1, ATF4, TRAF5 | More | | Hydrocortisone-valerate | hsa05169 | Epstein-Barr virus infection | 2.32E-02 | 9 | Q13547, O00463, Q16539, P42338, P07948, Q13761, P24522, P07766, P20963 | HDAC1, TRAF5, MAPK14, PIK3CB, LYN, RUNX3, GADD45A, CD3E, CD247 | More | | Hydrocortisone-valerate | hsa05202 | Transcriptional misregulation in cancer | 4.29E-03 | 13 | P14780, P27930, Q15744, Q16548, P11215, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, P12980, P24522 | MMP9, IL1R2, CEBPE, BCL2A1, ITGAM, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, LYL1, GADD45A | More | | Hydrocortisone-valerate | hsa05203 | Viral carcinogenesis | 2.10E-04 | 8 | Q12933, P42229, Q13547, Q15283, P58876, P62807, Q16778, O60814 | TRAF2, STAT5A, HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Hydrocortisone-valerate | hsa05204 | Chemical carcinogenesis | 1.77E-04 | 4 | Q16772, P09211, P78417, P11712 | GSTA3, GSTP1, GSTO1, CYP2C9 | More | | Hydrocortisone-valerate | hsa05206 | MicroRNAs in cancer | 2.97E-03 | 6 | P15311, P21860, P61978, P46531, P63279, P22105 | VIL2, ERBB3, HNRPK, NOTCH1, UBE2I, TNXB | More | | Hydrocortisone-valerate | hsa05230 | Central carbon metabolism in cancer | 1.12E-02 | 1 | P11413 | G6PD | More | | Hydrocortisone-valerate | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 5.53E-04 | 10 | P42338, O95267, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, CD4 | More | | Hydrocortisone-valerate | hsa05310 | Asthma | 1.62E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Hydrocortisone-valerate | hsa05321 | Inflammatory bowel disease | 1.09E-03 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Hydrocortisone-valerate | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Hydrocortisone-valerate | hsa05332 | Graft-versus-host disease | 1.76E-02 | 4 | P13765, P01375, P26715, Q13241 | HLA-DOB, TNF, KLRC1, KLRD1 | More | | Hydrocortisone-valerate | hsa05415 | Diabetic cardiomyopathy | 3.59E-02 | 1 | P11413 | G6PD | More | | |